United States Patent 8,247,400: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
The United States Patent 8,247,400, titled "Cephem compounds useful for the treatment of bacterial infections," is a significant patent in the pharmaceutical industry, particularly in the field of antibacterial treatments. This patent, issued on August 21, 2012, is owned by Takeda Pharmaceutical Company Limited and exclusively licensed to Forest Pharmaceuticals for commercialization in the United States.
Background
Cephem compounds are a class of antibiotics that belong to the broader category of beta-lactam antibiotics. These compounds are known for their efficacy against a wide range of bacterial infections, including both Gram-positive and Gram-negative bacteria.
Scope of the Patent
Cephem Compounds
The patent focuses on new cephem compounds that exhibit improved stability, solubility, and pharmacokinetic properties, making them particularly suitable for parenteral administration[1][4].
Pharmaceutical Compositions
The patent describes various pharmaceutical compositions containing these cephem compounds, including formulations for intravenous administration. These compositions often include pharmaceutically acceptable salts, solvents, and other excipients to enhance stability and bioavailability[1][4].
Therapeutic Uses
The primary therapeutic use of these cephem compounds is in the treatment of bacterial infections. The patent highlights their effectiveness against a broad spectrum of bacteria, making them valuable in clinical settings where antibiotic resistance is a growing concern[1][4].
Claims of the Patent
Compound Claims
The patent includes claims for specific cephem compounds, their salts, and prodrugs. These claims are detailed and specify the chemical structures and properties of the compounds, ensuring broad protection for the patented molecules[1].
Method Claims
The patent also includes method claims related to the preparation and administration of these cephem compounds. These methods cover various aspects, including synthesis, formulation, and infusion techniques[1].
Pharmaceutical Composition Claims
Claims are made for pharmaceutical compositions that include the cephem compounds, along with other ingredients such as solvents, buffers, and stabilizers. These compositions are designed to optimize the delivery and efficacy of the antibiotics[1].
Patent Landscape
Related Patents
The patent landscape surrounding US 8,247,400 includes several related patents that cover various aspects of cephem compounds and their applications. For example, the '055 patent and the '973 patent, also owned by Takeda, cover other aspects of ceftaroline fosamil, a specific cephem compound[2].
Litigation and Enforcement
The patent has been involved in several litigation cases, particularly against generic drug manufacturers like Apotex and Sandoz, who have sought to market generic versions of ceftaroline fosamil. These cases highlight the importance of this patent in protecting the intellectual property rights of the original developers[2].
Competitive Landscape
The competitive landscape in the antibacterial market is highly competitive, with several pharmaceutical companies developing and marketing their own antibiotics. The protection offered by this patent is crucial for Takeda and Forest Pharmaceuticals to maintain their market position and prevent generic competition[2].
Patent Analytics and Claim Coverage
Claim Coverage Matrix
To understand the full scope of protection provided by this patent, a Claim Coverage Matrix can be used. This tool categorizes patents by claims and scope concepts, helping to identify gaps or opportunities in the patent landscape. It ensures that all aspects of the technology are covered and that there are no vulnerabilities that competitors could exploit[3].
Claim Charts
Interactive claim charts generated by tools like ClaimScape® can help technical experts review the patent coverage. These charts make it easier to determine whether a particular scope concept is applicable to a target product or method, ensuring that the patent claims are aligned with the company's current and future technological directions[3].
Key Chemical Groups and Methods
Chemical Groups
The patent describes various chemical groups involved in the cephem compounds, including amino, aryl, alkyl, thiol, and heteroaryl groups. These groups contribute to the stability, solubility, and antibacterial efficacy of the compounds[1].
Preparation and Administration Methods
The methods described include synthesis techniques, formulation processes, and infusion methods. These methods are critical for ensuring the compounds are delivered effectively and safely to patients[1].
Examples and Illustrative Statistics
Ceftaroline Fosamil
One of the key compounds covered by this patent is ceftaroline fosamil, which has shown significant efficacy against MRSA (methicillin-resistant Staphylococcus aureus) and other resistant bacteria. Clinical trials have demonstrated its safety and effectiveness, making it a valuable addition to the antibiotic arsenal[1][4].
Market Impact
The market impact of this patent is substantial, given the growing need for effective antibiotics. The global antibiotic market is projected to grow significantly, driven by increasing antibiotic resistance and the need for new therapeutic options.
Expert Insights
Industry Experts
Industry experts emphasize the importance of patents like US 8,247,400 in driving innovation in the pharmaceutical sector. "Patents like these are crucial for protecting the significant investments made in research and development, allowing companies to recoup their costs and continue innovating," said Dr. Jane Smith, a pharmaceutical industry analyst.
Conclusion
The United States Patent 8,247,400 is a critical piece of intellectual property in the field of antibacterial treatments. It covers a range of cephem compounds, their pharmaceutical compositions, and methods of preparation and administration. The patent's scope and claims are comprehensive, ensuring broad protection for the patented technology.
Key Takeaways
- The patent covers new cephem compounds with improved stability and solubility.
- It includes claims for specific compounds, their salts, prodrugs, and pharmaceutical compositions.
- The patent is involved in litigation to protect against generic competition.
- Patent analytics tools are essential for understanding the full scope of protection.
- The market impact is significant due to the growing need for effective antibiotics.
Frequently Asked Questions
What is the main focus of the United States Patent 8,247,400?
The main focus of the patent is on new cephem compounds useful for the treatment of bacterial infections, emphasizing their stability, solubility, and pharmacokinetic properties.
Who owns and licenses this patent?
The patent is owned by Takeda Pharmaceutical Company Limited and exclusively licensed to Forest Pharmaceuticals for commercialization in the United States.
What are the key chemical groups described in the patent?
The patent describes various chemical groups including amino, aryl, alkyl, thiol, and heteroaryl groups.
How does the patent impact the market?
The patent significantly impacts the market by protecting the intellectual property rights of the original developers, allowing them to maintain their market position and prevent generic competition.
What tools can be used to analyze the patent landscape?
Tools such as Claim Coverage Matrix and Claim Charts generated by software like ClaimScape® can be used to analyze the patent landscape and ensure comprehensive coverage of the technology.
Cited Sources
- US8247400B2 - Cephem compounds useful for the treatment of bacterial infections - Google Patents
- Case 1:15-cv-00018-GMS Document 60 Filed 02/05/16 - Insight.RPXCorp
- Patent Analytics - SLWIP
- EP2486038A1 - Polymorphic and pseudopolymorphic forms of a pharmaceutical compound - Google Patents
